- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Prostate Cancer | Clinical
Frontline Treatment Approaches to Nonmetastatic CRPC
July 04, 2022
Returning to the patient case, experts review available frontline treatment options in the setting of nonmetastatic castration-resistant prostate cancer.
Nonmetastatic CRPC: Importance of Patient Risk Status and Genetic Testing
July 04, 2022
A brief review of the prevalence of familial risk and other high-risk factors for prostate cancer, followed by recommendations for patient follow-up and genetic testing.
Case 1: A 59-Year-Old Man With Nonmetastatic CRPC
June 27, 2022
Panelists center their discussion on a real-world patient case of nonmetastatic castration-resistant prostate cancer managed with surgery and adjuvant therapy.
Overview of Prostate Cancer and Treatment Modalities
June 27, 2022
Experts provide comprehensive insight on prostate cancer, covering its prevalence, subtypes, and the systemic treatment armamentarium.
SPOTLIGHT Shines on Inadequacy of Standard Imaging in Prostate Cancer
June 24, 2022
Mark T. Fleming, MD, discusses the potential impact of positive data from the phase 3 SPOTLIGHT study, which assessed the how 18F-rhPSMA-7.3 PET scan use in male patients with biochemical recurrence of prostate cancer affects upstaging in comparison with conventional imaging.
Examining Molecular Subtyping in Prostate Cancer
June 24, 2022
In an interview with Targeted Oncology, Adam Weiner, MD, discussed molecular subtyping for prostate cancer based on basal and luminal cell-of-origin and how such research may impact the future of this space.
Sabizabulin for the Treatment of Men With mCRPC
June 17, 2022
Mark Markowski, MD, PhD, discusses the design of a phase 1B/2 study of sabizabulin in men with metastatic castration-resistant prostate cancer who have had treatment and progression on an androgen receptor–targeting agent.
CARD Trial Shows Survival and QOL Benefits of Cabazitaxel in mCRPC
June 15, 2022
During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the results of the CARD trial of cabazitaxel for patients with metastatic castration-resistant prostate cancer. This is part 1 of 2 articles based on this event.
Initial Risk Stratification of Localized Prostate Cancer
June 10, 2022
Tanya Dorff, MD, reviews guidelines for initial risk stratification of patients with localized prostate cancer, and the choices in imaging strategies.
Radiotherapy Can Be Paired with Next-Gen Hormonal Therapy in Phase 3 HRLPC Trials
June 09, 2022
According to the phase 3 ATLAS trial, radiotherapy can be administered with next-generation hormonal therapy in phase 3 trials of patients with high-risk localized or locally advanced prostate cancer.